Phathom Pharmaceuticals (PHAT) Resumen de Acciones
Phathom Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de tratamientos para enfermedades gastrointestinales en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
PHAT Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Phathom Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$8.37 |
| Máximo en las últimas 52 semanas | US$18.31 |
| Mínimo de 52 semanas | US$8.21 |
| Beta | 0.51 |
| Cambio en 1 mes | -1.65% |
| Variación en 3 meses | -19.29% |
| Cambio de 1 año | -30.60% |
| Variación en 3 años | -37.86% |
| Variación en 5 años | -74.96% |
| Variación desde la OPV | -65.98% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 09
PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing
Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.Seeking Alpha • Sep 09
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 15
PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline
Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.Recent updates
Actualización de narrativa • Sep 09
PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing
Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.Seeking Alpha • Sep 09
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking AlphaActualización de narrativa • Aug 15
PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline
Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.Actualización de narrativa • Jun 15
PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing
Analysts have raised their price target on Phathom Pharmaceuticals to $13.62, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E following recent research support. What's in the News Phathom highlighted extensive clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago.Actualización de narrativa • Jun 01
PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline
Analysts have adjusted their price target on Phathom Pharmaceuticals to $23.70. This reflects updated views on the discount rate, long-term margin potential, and future P/E assumptions following recent research commentary.Actualización de narrativa • May 02
PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline
Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.Actualización de narrativa • Apr 15
PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability
Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.Actualización de narrativa • Apr 01
PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang
Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.Actualización de narrativa • Mar 18
PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions
Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.Actualización de narrativa • Mar 04
PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk
Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.Actualización de narrativa • Feb 18
PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability
Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.Actualización de narrativa • Feb 04
PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside
Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.Actualización de narrativa • Jan 20
PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside
Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.Artículo de análisis • Jan 08
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...Actualización de narrativa • Jan 06
PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.Actualización de narrativa • Dec 16
PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum
Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.Actualización de narrativa • Dec 01
PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.Actualización de narrativa • Nov 17
PHAT: Early Clinical Trial Progress Will Drive Shares Higher
Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.Actualización de narrativa • Nov 01
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.Actualización de narrativa • Sep 04
Gastroenterology Focus Will Unlock Enduring Market Potential
Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.Artículo de análisis • Jul 19
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...Artículo de análisis • Jun 02
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...Nueva narrativa • May 09
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.Artículo de análisis • Apr 18
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...Seeking Alpha • Dec 11
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Following Up On Phathom Pharmaceuticals
Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking AlphaRentabilidad de los accionistas
| PHAT | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -7.5% | -3.0% | -0.2% |
| 1Y | -30.6% | 45.8% | 14.8% |
Rentabilidad vs. Industria: Los resultados de PHAT fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 45.8% el año pasado.
Rentabilidad vs. Mercado: PHAT obtuvo unos resultados inferiores a los del mercado US, que fueron del 14.8% el año pasado.
Volatilidad de los precios
| PHAT volatility | |
|---|---|
| PHAT Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: PHAT no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PHAT (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2018 | 371 | Steve Basta | www.phathompharma.com |
Phathom Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de tratamientos para enfermedades gastrointestinales en Estados Unidos. Desarrolla VOQUEZNA, que ha completado ensayos clínicos de fase III para el tratamiento de la enfermedad por reflujo gastroesofágico erosiva (ERGE) y la acidez estomacal relacionada en adultos; y VOQUEZNA Triple Pak y VOQUEZNA Dual Pak que han completado ensayos clínicos de fase III para el tratamiento de Helicobacter pylori, así como VOQUEZNA y vonoprazan para el tratamiento de la acidez estomacal asociada con ERGE no erosiva y esofagitis eosinofílica en adultos y adolescentes. La empresa se constituyó en 2018 y tiene su sede en Florham Park, Nueva Jersey.
Resumen de fundamentos de Phathom Pharmaceuticals, Inc.
| Estadísticas fundamentales de PHAT | |
|---|---|
| Capitalización bursátil | US$688.66m |
| Beneficios(TTM) | -US$99.07m |
| Ingresos (TTM) | US$239.66m |
2.8x
Ratio precio-ventas (PS)-6.7x
Ratio precio-beneficio (PE)¿Está PHAT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PHAT | |
|---|---|
| Ingresos | US$239.66m |
| Coste de los ingresos | US$40.93m |
| Beneficio bruto | US$198.73m |
| Otros gastos | US$297.81m |
| Beneficios | -US$99.07m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.25 |
| Margen bruto | 82.92% |
| Margen de beneficio neto | -41.34% |
| Ratio deuda/patrimonio | -159.6% |
¿Cómo se ha desempeñado PHAT a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/10 01:11 |
| Precio de las acciones al final del día | 2026/09/10 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Phathom Pharmaceuticals, Inc. está cubierta por 16 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jenna Davidner | Barclays |
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |